Joshua J. Meeks, MD, PhD, explains how enfortumab vedotin plus pembrolizumab is reshaping organ preservation in MIBC.
|Videos|March 14, 2011
Dr. Alter Discusses Research at JTCC
Author(s)Robert S. Alter, MD
Dr. Robert Alter on Current Research at John Theurer Cancer Center
Advertisement
Robert S. Alter, M.D. Co-chief, Urologic Oncology, John Theurer Cancer Center, discusses research taking place at the John Theurer Cancer Center, in the spring of 2011.
Advertisement
Related to this article
The PCR-based OncoMate MSI Dx Analysis System can now identify patients with MSI-H solid tumors who may be eligible for pembrolizumab.
Anktiva plus BCG improved efficacy vs BCG alone in cohort A of QUILT-2.005 in BCG-naive NMIBC.
The FDA set a June 25, 2027, target action date for gedatolisib plus fulvestrant in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer.
The top 5 OncLive TV videos of the week cover insights in NSCLC, gynecologic cancers, CRC, multiple myeloma, and NMIBC.
Katie S. Murray, DO, discusses how efficacy, toxicity, patient preferences, and treatment logistics guide BCG-unresponsive NMIBC care.
Vignesh T. Packiam, MD, reviews why improved BCG outcomes support its first-line use, with gemcitabine/docetaxel as a BCG-sparing option.
Experts break down key kidney cancer data and trends from the 2026 ESMO Congress.
Advertisement
Advertisement
Trending on OncLive
1
Mo-Rez Responses Span B7-H4 Expression Levels in Platinum-Resistant Ovarian Cancer in BEHOLD-1 Biomarker Analysis
2
Genomic Testing, Toxicity, and Sequencing Shape Treatment Decisions in Advanced Prostate Cancer
3
FDA Approves Pimicotinib for Symptomatic TGCT
4
Dr Natsuhara on Treatment Advances and Research Considerations in TNBC
5